KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Deferred Taxes: 2021-2023

Historic Deferred Taxes for Moderna (MRNA) over the last 3 years, with Dec 2023 value amounting to -$33.0 million.

  • Moderna's Deferred Taxes rose 68.57% to -$33.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $901.0 million, marking a year-over-year increase of 255.88%. This contributed to the annual value of $901.0 million for FY2023, which is 255.88% up from last year.
  • Moderna's Deferred Taxes amounted to -$33.0 million in Q4 2023, which was down 102.25% from $1.5 billion recorded in Q3 2023.
  • In the past 5 years, Moderna's Deferred Taxes registered a high of $1.5 billion during Q3 2023, and its lowest value of -$310.0 million during Q1 2023.
  • Its 3-year average for Deferred Taxes is $416,667, with a median of -$101.0 million in 2022.
  • Per our database at Business Quant, Moderna's Deferred Taxes slumped by 945.45% in 2022 and then skyrocketed by 1,609.28% in 2023.
  • Over the past 3 years, Moderna's Deferred Taxes (Quarterly) stood at -$229.0 million in 2021, then spiked by 54.15% to -$105.0 million in 2022, then soared by 68.57% to -$33.0 million in 2023.
  • Its Deferred Taxes stands at -$33.0 million for Q4 2023, versus $1.5 billion for Q3 2023 and -$220.0 million for Q2 2023.